PRISM BioLab Co.,LTD (TYO:206A)

Market Cap	7.17B -32.9%
Revenue (ttm)	684.61M +83.8%
Net Income	-927.75M
EPS	-25.26
Shares Out	36.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	317,800
Average Volume	754,120
Open	196.00
Previous Close	195.00
Day's Range	189.00 - 196.00
52-Week Range	132.00 - 282.00
Beta	n/a
RSI	51.49
Earnings Date	May 14, 2026

About PRISM BioLab Co.,LTD

PRISM BioLab Co.,LTD engages in the research and development of pharmaceuticals using its proprietary drug discovery platform technology, PepMetics Technology. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has a strategic collaboration with Receptor.AI Inc. for the development of an AI-integrated drug discovery platform. The company was founded in 2006 and is based in Fujis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Country: Japan
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 206A

Financial Performance

In fiscal year 2025, PRISM BioLab Co.,LTD's revenue was 677.33 million, an increase of 121.62% compared to the previous year's 305.62 million. Losses were -833.70 million, -20.56% less than in 2024.